Futura Medical Receives Recommendation for Approval of MED3000 from EU Notified Body

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces that the EU Notified Body has successfully completed its review of the Company’s Technical Dossier for MED3000 with a recommendation to certificate MED3000 as a Class 2B approved medical device.  Once the certificate is received, Futura’s breakthrough, topical gel formulation MED3000, will become the first pan-European topical treatment for erectile dysfunction (“ED”) available without the need of a doctor’s prescription.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...